von Willebrand Factor Propeptide: A Potential Disease Biomarker Not Affected by ABO Blood Groups | Zendy

Marianor Mahat | Zendy; Zaidah Abdullah Wan | Zendy; Maraina C.H. Che | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

von Willebrand Factor Propeptide: A Potential Disease Biomarker Not Affected by ABO Blood Groups

Author(s) -

Marianor Mahat,

Zaidah Abdullah Wan,

Maraina C.H. Che

Publication year - 2015

Publication title -

biomarker insights

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.075

H-Index - 31

ISSN - 1177-2719

DOI - 10.4137/bmi.s24353

Subject(s) - abo blood group system , biomarker , von willebrand factor , medicine , protein precursor , pathophysiology , disease , immunology , platelet , biology , biochemistry , gene

Epidemiological studies have shown that vascular-related disorders are associated with high von Willebrand factor antigen (VWF:Ag) and VWF propeptide (VWFpp). VWFpp is secreted together with VWF:Ag upon endothelial cell activation, hence it could be a potential biomarker. This study was conducted to compare between VWFAg and VWFpp levels among 30 healthy individuals and 42 patients with high levels of VWF:Ag in different medical conditions and ABO blood groups. VWFpp levels were strongly correlated with VWF:Ag. VWF:Ag and VWFpp levels were significantly increased in patients compared to healthy individuals. VWFpp is not affected by ABO blood group in both healthy individual and patient groups unlike VWF:Ag. As expected, this study showed that VWFpp levels increased in parallel with VWF:Ag levels in patients with diseases associated with endothelial activation. VWFpp though nonspecific is a potential biomarker reflecting underlying pathophysiological changes in various medical conditions with an additional advantage of not being influenced by ABO blood groups.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research